Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-depot SQ house dust mite immunotherapy for atopic dermatitis
2005-004675-37Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) and house dust mite allergy comparing ALK-depot SQ 510 Milbenmischung with Placebo (2 arms). Primary endpoint: SCORAD intensity score. Started Dec 2005; status: completed.
02
Drugs
ALK-depot SQ 510 Milbenmischung
03
Conditions
atopic dermatitis (AD)house dust mite allergy
Beyond the preview
Go deeper on 2005-004675-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004675-37.